Skip to main content

Table 1 Selection of study subjects

From: Healthcare utilization and costs in patients beginning pharmacotherapy for generalized anxiety disorder: a retrospective cohort study

 

Patients

Number of patients with ≥ 2 outpatient claims for GAD and

285,820

≥ 1 claims for pharmacotherapy used to treat GAD and

167,538

≥ 1 claims with GAD diagnosis on index date or during 90-day period immediately prior and

55,791

≥ 12 months enrollment prior to index date* and

22,678

≥ 12 months enrollment following index date* and

14,407

No evidence of receipt of any benzodiazepine, SSRI or SNRI in the year prior to index date and**

11,202

No Medicaid insurance and

11,111

Aged < 65 years or

10,398

Aged ≥ 65 years and not enrolled in Medicare supplemental or capitated plans

119

Total of above and

10,517

No missing information on therapy-days on prescription for index drug

10,275

  1. *First-noted claim for medication of interest during study period
  2. **Including agents that are and are not recommended for use in GAD
  3. GAD: generalized anxiety disorder; SSRI: Selective serotonin reuptake inhibitor; SNRI: Serotonin-norepinephrine reuptake inhibitor